J&J Sirturo Wins FDA Approval to Treat Drug-Resistant TB
This article is for subscribers only.
Johnson & Johnson won accelerated U.S. Food and Drug Administration approval for its tuberculosis tablet Sirturo, the first medicine in 40 years that provides a new way to treat the contagious lung infection.
The FDA cleared Sirturo to be added to existing therapies for use by adults whose illness is resistant to multiple drugs, New Brunswick, New Jersey-based J&J said today in a statement. The FDA cleared Sirturo based on the second of what are typically three clinical trial phases, an option the agency has when a drug treats a serious disease and fills an unmet need.